Financial Performance - Net profit attributable to shareholders increased by 32.54% to CNY 117,116,082.56 for the reporting period[10] - Operating revenue for the period was CNY 909,294,905.00, reflecting a 2.02% increase year-on-year[10] - Basic earnings per share rose by 30.00% to CNY 0.13 for the reporting period[10] - The net profit after deducting non-recurring gains and losses increased by 38.20% to CNY 119,868,861.00[10] - The net profit for the current period reached ¥130,796,187.47, compared to ¥97,431,768.58 in the previous period, indicating a growth of about 34.2%[63] - The total profit for the current period was ¥404,461,470.76, compared to ¥305,352,572.43 in the previous period, reflecting an increase of about 32.41%[76] - The profit attributable to the parent company's shareholders was ¥290,822,049.48, up from ¥211,667,094.16, which is an increase of approximately 37.36%[76] - The total comprehensive income for the current period was ¥325,483,834.00, compared to ¥230,869,453.08 in the previous period, indicating a growth of about 41.00%[80] Assets and Liabilities - Total assets increased by 7.31% to CNY 5,840,943,609.42 compared to the end of the previous year[10] - The company's total assets amounted to ¥3,812,850,626.01, compared to ¥3,668,116,819.21 in the previous year, marking an increase of about 3.9%[55] - The total liabilities decreased slightly to ¥1,246,286,286.96 from ¥1,257,599,287.85, showing a reduction of about 0.9%[52] - The company reported a decrease in accounts payable to ¥111,154,057.73 from ¥169,743,819.58, a decline of approximately 34.4%[52] - The total liabilities amounted to 2,732,960,522.70 CNY, unchanged from the previous period[112] - The company’s long-term borrowings were recorded at 1,070,951,114.29 CNY, unchanged from the previous period[109] Cash Flow - The net cash flow from operating activities decreased by 64.12% to CNY 54,259,401.20 compared to the same period last year[10] - Cash flow from operating activities generated a net inflow of CNY 402,960,442.22, up from CNY 237,880,404.02 in the prior period, showcasing strong operational performance[88] - The company reported a net cash outflow from investing activities of CNY -233,697,979.17, a decline from a net inflow of CNY 27,620,061.76 in the prior period, indicating increased investment expenditures[93] - Cash flow from financing activities resulted in a net outflow of CNY -38,500,611.59, an improvement from a net outflow of CNY -93,456,544.66 in the previous year[93] Shareholder Information - The company reported a total of 26,000 shareholders at the end of the reporting period[15] - The largest shareholder, Xianju County State-owned Assets Investment Group, holds 21.55% of the shares[15] - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[20] Research and Development - Research and development expenses increased by 31.79% year-on-year, an increase of 26.49 million yuan, mainly due to increased R&D expenditures[25] - Research and development expenses increased significantly to ¥38,580,047.98 from ¥19,783,317.76, marking a rise of approximately 94.8%[67] - The company's R&D expenses increased to ¥109,797,711.66 from ¥83,312,630.38, marking a rise of about 31.93%[73] Income and Other Revenue - Other income increased by 71.12% year-on-year, an increase of 7.70 million yuan, mainly due to increased subsidy income[25] - Investment income increased by 130.09% year-on-year, an increase of 11.82 million yuan, mainly due to increased profits from associated companies[25] - Cash received from tax refunds increased by 14,224.26% year-on-year, an increase of 16.19 million yuan, mainly due to export tax rebates received[25] - The investment income from joint ventures and associates was ¥3,541,188.98, significantly higher than ¥1,217,702.80 in the previous period, reflecting an increase of approximately 190.5%[63] - The company experienced a significant increase in investment income, which rose to ¥18,533,016.01 from ¥10,830,223.32, representing a growth of approximately 71.00%[73] Cost Management - Total operating costs decreased to ¥754,198,140.59 from ¥763,231,704.00, reflecting a reduction of about 1.4%[56] - The company paid CNY 212,288,576.27 for goods and services, a decrease from CNY 229,851,818.97 in the prior period, suggesting improved cost management[99]

Financial Performance - Net profit attributable to shareholders increased by 32.54% to CNY 117,116,082.56 for the reporting period[10] - Operating revenue for the period was CNY 909,294,905.00, reflecting a 2.02% increase year-on-year[10] - Basic earnings per share rose by 30.00% to CNY 0.13 for the reporting period[10] - The net profit after deducting non-recurring gains and losses increased by 38.20% to CNY 119,868,861.00 for the reporting period[10] - The company's net profit for the current period is CNY 130,796,187.47, an increase of 34.3% compared to CNY 97,431,768.58 in the previous period[57] - Total operating revenue for the current period reached ¥2,769,045,484.21, an increase of 4.49% compared to ¥2,650,144,267.02 in the previous period[71] - Net profit for the current period was ¥326,346,375.05, representing a 42% increase from ¥230,038,441.95 in the previous period[74] - The total profit for the current period is CNY 158,424,772.69, an increase of 25.6% from CNY 126,102,283.59 in the previous period[57] - The company reported a total profit of ¥404,461,470.76, an increase from ¥305,352,572.43, reflecting a growth of 32.4%[74] Assets and Liabilities - Total assets increased by 7.31% to CNY 5,840,943,609.42 compared to the end of the previous year[10] - The company's total assets amounted to ¥3,812,850,626.01, compared to ¥3,668,116,819.21 in the previous year, marking an increase of about 3.9%[53] - The total liabilities decreased slightly to ¥1,246,286,286.96 from ¥1,257,599,287.85, indicating a reduction of approximately 0.9%[50] - The total liabilities were $2.73 billion, with current liabilities at $1.61 billion and non-current liabilities at $1.13 billion[109] - The company reported a total liability of CNY 1,257,599,287.85, with current liabilities at CNY 1,016,165,734.86 and non-current liabilities at CNY 241,433,552.99[118] Cash Flow - The net cash flow from operating activities decreased by 64.12% to CNY 54,259,401.20 compared to the same period last year[10] - Cash inflow from operating activities reached ¥2,546,877,983.17, up from ¥2,298,575,381.00, showing a growth of approximately 10.8%[87] - Net cash flow from operating activities was ¥402,960,442.22, compared to ¥237,880,404.02 in the previous period, representing a substantial increase[88] - The company received tax refunds of ¥16,312,640.08, significantly higher than ¥113,881.24 in the previous period, indicating improved cash management[90] - The company reported a net increase in cash and cash equivalents of ¥140,735,827.24, compared to ¥175,279,525.61 in the previous period, indicating a decrease in cash generation[93] Research and Development - Research and development expenses increased by 31.79% year-on-year, an increase of 26.49 million yuan, mainly due to increased R&D spending[23] - Research and development expenses increased significantly to CNY 38,580,047.98, compared to CNY 19,783,317.76 in the previous period, marking a rise of 94.8%[65] - Research and development expenses increased to ¥109,797,711.66, up from ¥83,312,630.38, marking a growth of 31.93%[71] Equity and Shareholder Information - The total net assets attributable to shareholders increased by 7.40% to CNY 2,826,441,545.49 compared to the end of the previous year[10] - The total equity attributable to shareholders reached ¥2,566,564,339.05, up from ¥2,410,517,531.36, reflecting an increase of approximately 6.5%[53] - The owner's equity totaled $2.71 billion, with the equity attributable to shareholders amounting to $2.63 billion[109] - The company reported a significant increase in undistributed profits, which rose to ¥603,492,581.57 from ¥447,445,773.88, reflecting a growth of approximately 34.9%[53] Compliance and Adjustments - The company adjusted its financial statements to reflect the new financial instrument standards, impacting the classification of certain assets[100] - The report indicates a focus on compliance with new financial regulations without retrospective adjustments affecting previous financial indicators[118] - The company has not undergone an audit for the third quarter report, which may affect the reliability of the financial data presented[119]

证券代码：002332 证券简称：仙琚制药 公告编号：2019-039 浙江仙琚制药股份有限公司 关于参加浙江辖区上市公司投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的沟通交流，浙江仙琚制药股份有限公司（以下简称 "公司"）将参加由中国证监会浙江证监局指导、浙江上市公司协会与深圳市全 景网络有限公司共同举办的"沟通促发展 理性共成长"辖区上市公司投资者网 上集体接待日主题活动，现将有关事项公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的网 上平台举行，投资者可以登录"全景·路演天下"网站（http://rs.p5w.net） 参与公司本次投资者网上接待日活动。网上互动交流时间为 2019 年 11 月 5 日（星 期二）下午 15:30-17:00。 届时公司财务总监王瑶华女士、董事会秘书张王伟先生及相关工作人员将采 用网络远程方式，与投资者就公司治理、发展战略、经营状况、可持续发展等投 资者所关心的问题进行沟通。 欢迎广大投资者积极参与。 特此公告。 浙江仙琚制药股份有限公司 ...

Financial Performance - The company's operating revenue for the first half of 2019 was CNY 1,859,750,579.21, representing a 5.74% increase compared to CNY 1,758,815,023.25 in the same period last year[26]. - The net profit attributable to shareholders of the listed company reached CNY 173,705,966.92, a significant increase of 40.88% from CNY 123,302,397.70 in the previous year[26]. - The net profit after deducting non-recurring gains and losses was CNY 163,394,977.46, up 41.28% from CNY 115,656,689.67 year-on-year[26]. - The net cash flow from operating activities surged to CNY 348,701,041.02, marking a 302.35% increase compared to CNY 86,666,970.86 in the same period last year[26]. - Basic earnings per share rose to CNY 0.19, reflecting a 46.15% increase from CNY 0.13 in the previous year[26]. - The company achieved operating revenue of RMB 1,859.75 million, representing a year-on-year growth of 5.74%[41]. - The net profit attributable to shareholders was RMB 173.71 million, showing a significant year-on-year increase of 40.88%[41]. - The company reported a gross margin of 59.50% in the pharmaceutical sector, an increase of 1.92% from the previous year[68]. Assets and Liabilities - Total assets at the end of the reporting period amounted to CNY 5,803,727,916.08, a 6.62% increase from CNY 5,443,275,372.92 at the end of the previous year[26]. - The net assets attributable to shareholders of the listed company were CNY 2,723,305,590.56, up 3.48% from CNY 2,631,668,611.96 at the end of the previous year[26]. - The company's total liabilities were CNY 2,987,029,096.30, compared to CNY 2,732,960,522.70, which is an increase of approximately 9.3%[191]. - The total equity remained stable at CNY 2,816,698,819.78, with no changes in the share capital of CNY 916,212,166.00[193]. - Cash and cash equivalents at the end of the reporting period amounted to CNY 1,051,753,207.85, representing 18.12% of total assets, a decrease of 1.44% compared to the previous year[72]. - Accounts receivable reached CNY 918,760,845.21, accounting for 15.83% of total assets, with a slight increase of 0.08% year-on-year[72]. - Inventory stood at CNY 700,139,173.00, making up 12.06% of total assets, down by 0.83% from the previous year[72]. - Fixed assets increased to CNY 1,093,885,753.22, representing 18.85% of total assets, an increase of 2.00% year-on-year[72]. Shareholder Information - The largest shareholder, Xianju County State-owned Assets Investment Group Co., Ltd., holds 21.55% of the shares, totaling 197,488,304 shares[150]. - The total number of shares before the recent changes was 916,212,166, with 1.33% being restricted shares and 98.67% being unrestricted shares[146]. - The total number of unrestricted shares held by the top ten shareholders amounts to 318,000,000 shares, reflecting significant concentration of ownership[156]. - The report indicates that there were no changes in the shareholding structure among the top ten shareholders, maintaining stability[156]. - The company has not implemented any share buyback programs during the reporting period[146]. Operational Highlights - The company focuses on the steroid hormone sector, maintaining steady sales growth through specialization in therapeutic areas[41]. - The integration of raw materials and formulations has helped establish a comprehensive cost advantage[41]. - The company plans to enhance international registration and certification efforts to increase market share in the international standards market for raw materials[41]. - The company will continue to optimize its marketing system and strengthen the integration of subsidiaries[41]. - The company achieved a revenue of CNY 185,975.06 million in the first half of 2019, representing a year-on-year growth of 5.74%[56]. - Sales revenue from self-operated formulation products was CNY 8,920 million, an increase of 10% year-on-year[56]. - The company has established stable business relationships with over 100 domestic steroid drug manufacturers, maintaining a stable market share[47]. - The company has completed the installation and debugging of new equipment at its Yangfu raw material drug factory, with 13 products passing GMP certification[48]. - The company has received re-registration approval for 37 products, enhancing its product portfolio[49]. - The company is actively pursuing the development of a new drug, Omegastone Sodium, currently in Phase IIb research[58]. - The company has established business connections with over 40 foreign pharmaceutical companies across more than 30 countries[47]. Research and Development - Research and development expenses increased by 38.48% to ¥65,523,586.04 from ¥47,315,613.16, primarily due to increased R&D expenditures during the period[64]. - The company aims to strengthen talent development and attract high-level professionals to support sustainable growth amid international competition[95]. - New drug research and development involves high investment and risk, with uncertainties regarding market conditions and competition affecting post-launch revenue expectations[94]. Environmental and Regulatory Compliance - Zhejiang Xianju Pharmaceutical Co., Ltd. reported a total COD emissions of 40.04 tons, ammonia nitrogen emissions of 2.62 tons, total phosphorus emissions of 0.38 tons, and total nitrogen emissions of 4.50 tons during the reporting period[132]. - The company has wastewater treatment facilities with a designed capacity of 2200 tons/day, 400 tons/day, and 1400 tons/day across different plants, achieving an operational stability rate of over 99%[135]. - The company’s wastewater discharge complies with the "Comprehensive Discharge Standard for Wastewater" GB8978-1996, with COD limits of ≤480 mg/L for the Chengnan plant and ≤500 mg/L for the Taizhou plant[135]. - The company has implemented an emergency response plan for environmental incidents, with designated emergency pools of 300 m³, 1800 m³, and 400 m³ at various facilities[135]. Risks and Challenges - The company faces risks from industry policy changes and the need to complete consistency evaluations for generic drugs, which may impact production and operational stability[89][90]. - The implementation of medical insurance cost control and secondary negotiation policies has increased the requirements for the company's sales channel planning and bidding department coordination capabilities[92]. - The company faces rising comprehensive management costs due to increased fixed asset depreciation, financial costs, labor costs, and sales expenses, which may impact profits[93]. - The company has not experienced any major litigation or arbitration matters during the reporting period[105]. Corporate Governance - The board of directors confirmed the accuracy and completeness of the financial report, ensuring no significant omissions or misleading statements[6]. - The company has approved a total external guarantee amount of 26 million yuan, with no actual guarantees occurring during the reporting period[120]. - The company has no violations regarding external guarantees during the reporting period[130]. - The financial report for the first half of 2019 was not audited[176].

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the year 2018, representing a year-on-year growth of 15%[19] - The net profit attributable to shareholders was 250 million RMB, an increase of 20% compared to the previous year[19] - The company's operating revenue for 2018 was CNY 3,621,754,713.06, representing a year-on-year increase of 26.97%[27] - The net profit attributable to shareholders for 2018 was CNY 301,362,969.27, an increase of 45.85% compared to the previous year[27] - The net profit after deducting non-recurring gains and losses was CNY 282,371,781.88, reflecting a growth of 51.00% year-on-year[30] - The basic and diluted earnings per share for 2018 were both CNY 0.33, up 43.48% from CNY 0.23 in 2017[30] - The gross margin improved to 45%, up from 42% in the previous year, indicating better cost management[19] - The company achieved a revenue of 362,175.47 million CNY, representing a year-on-year growth of 26.97%[44] - The net profit attributable to shareholders was 30,136.30 million CNY, with a year-on-year increase of 45.85%[44] - The company reported a weighted average return on equity of 12.05% for 2018, up from 9.01% in 2017[30] Dividend Distribution - The company plans to distribute a cash dividend of 0.65 RMB per 10 shares, totaling approximately 59.5 million RMB[7] - The company declared a cash dividend of CNY 0.65 per 10 shares, totaling CNY 59,553,790.79, which is 100% of the distributable profit[165] - The total distributable profit at the end of the period was CNY 447,445,773.88[165] - The cash dividend payout ratio is in compliance with the minimum requirement of 20% for companies in a growth phase with significant capital expenditures[165] Market Expansion and Strategy - Future outlook includes an expansion into international markets, targeting a 25% increase in overseas sales by 2020[19] - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence[19] - The company plans to continue expanding its product lines and market presence in the pharmaceutical industry[39] - The company aims to build two platforms: manufacturing and sales, focusing on integration and efficiency to enhance its market position[132] - The company aims to enhance its international raw material drug business management by focusing on technical integration, international registration capabilities, and market policy research, with a specific emphasis on the steroid hormone industry[133] - The sales strategy will concentrate on three therapeutic areas: anesthesia, gynecology, and respiratory, while continuously launching new products to fill market gaps and expand into new indications[134] Research and Development - The company has invested 200 million RMB in R&D, focusing on new drug development and technological advancements[19] - The company completed 13 technical innovation projects for active pharmaceutical ingredients, significantly improving R&D efficiency[68] - The company achieved GMP certification for products like Vecuronium and Rocuronium, laying a solid foundation for international market expansion[70] - The company is actively working on the consistency evaluation of generic drugs, which is crucial for maintaining market competitiveness[149] - The company acknowledges the high risks associated with new drug development, including long cycles and regulatory challenges, and is refining its R&D strategy[153] Risk Management - The company identified key risks including raw material price fluctuations and regulatory changes, which could impact future performance[7] - The company has faced risks related to policy changes in the healthcare system, including cost control measures and drug pricing policies, which could impact operations[148] - Fluctuations in raw material prices pose a risk to product costs, and the company aims to enhance its product line through high-end international registrations[150] - The company anticipates challenges from drug price reductions due to new pricing policies and is focusing on innovative product development to mitigate these risks[151] - Rising comprehensive management costs, including depreciation and labor costs, are expected to impact profitability, prompting the company to enhance cost control measures[152] Asset Management - Total assets at the end of 2018 were CNY 5,443,275,372.92, marking a 6.01% increase from the previous year[30] - The net assets attributable to shareholders at the end of 2018 were CNY 2,631,668,611.96, an increase of 11.83% year-on-year[30] - Other receivables increased by 831 million CNY, a growth of 36.3%, mainly due to an increase in dividends receivable[50] - Held-for-sale assets increased by 4,230 million CNY, a 100% growth, primarily due to the reclassification of policy-related relocation assets[50] - The company has not disposed of any significant assets during the reporting period, maintaining its asset base[123] Operational Efficiency - The company completed the installation and debugging of most production lines in its new raw material drug factory, with subsequent lines to receive GMP certification[55] - The production system improved management efficiency and compliance, with 15 product production license applications approved and 32 customer audits conducted throughout the year[69] - The company implemented an ERP system, enhancing information support capabilities and improving financial control through comprehensive budget management[71] - The sales company focused on "compliance" and "internal control," effectively curbing unreasonable expenses, leading to significant improvements in management status[65] Corporate Governance - The company maintained a strong governance structure, achieving an A-level assessment in information disclosure for seven consecutive years[74] - The company will ensure timely and accurate reporting in compliance with regulatory requirements, enhancing corporate governance and meeting disclosure standards[144] - The company has fulfilled all commitments made by its actual controllers and shareholders during the reporting period[167] Subsidiaries and Acquisitions - The company established two new subsidiaries in August 2018, acquiring a 70% stake in Xianju Pharmaceutical Technology Company and a 100% stake in Xianju Hong Kong Company[86] - The company acquired 100% ownership of NewChem in Italy, which generated an operating income of 56,315.63 million yuan during the reporting period, focusing on raw materials and steroid drug research[128] - Following the acquisition of Newchem and Effechem, the company has significant goodwill on its balance sheet, which will be tested for impairment annually[155] Financial Health - The company reported a total of 1,046,898,876.90 CNY in accounts receivable, reflecting a significant increase from the previous year's reported figure of 434,538,951.67 CNY[183] - The company reported a management expense of 182,936,922.12 CNY and R&D expenses of 88,145,108.47 CNY[183] - The company received government subsidies amounting to 11,738,400 CNY, which were reported in the cash flow statement[182]

Financial Performance - The company's revenue for Q1 2019 was ¥835,738,416.97, representing a 0.70% increase compared to ¥829,940,103.40 in the same period last year[10]. - Net profit attributable to shareholders was ¥58,010,342.60, a significant increase of 43.23% from ¥40,501,223.77 in the previous year[10]. - Basic and diluted earnings per share both increased by 50.00% to ¥0.06 from ¥0.04 in the previous year[10]. - Net profit for the current period was ¥73,803,935.73, up from ¥49,166,573.45 in the previous period, indicating a significant increase of approximately 50.2%[57]. - The net profit attributable to the parent company was ¥58,010,342.60, compared to ¥40,501,223.77 in the previous period, reflecting an increase of around 43.2%[57]. - The company reported a total profit of ¥93,143,977.57, compared to ¥69,988,303.55 in the previous period, showing an increase of about 33.2%[57]. - Total comprehensive income reached ¥23,972,321.17, an increase from ¥19,228,564.19 in the previous period[67]. Cash Flow - The net cash flow from operating activities improved to ¥102,508,038.15, a remarkable increase of 181.21% compared to a negative cash flow of ¥126,233,633.02 in the same period last year[10]. - Cash inflow from operating activities totaled ¥794,392,215.40, slightly up from ¥790,099,095.83 in the previous period[71]. - Cash outflow from operating activities was ¥691,884,177.25, down from ¥916,332,728.85 year-over-year[71]. - Total cash outflow for operating activities was ¥287,756,258.29, down from ¥373,717,797.10 year-over-year[76]. - Net cash flow from investing activities was negative at ¥20,865,453.73, compared to a negative ¥10,606,156.46 in the previous period[74]. - Net cash flow from financing activities decreased to negative ¥4,530,098.04 from positive ¥51,305,188.08 year-over-year[74]. - The net increase in cash and cash equivalents was $31.08 million, a turnaround from a decrease of $25.05 million in the previous period[80]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,598,109,969.57, reflecting a 2.84% increase from ¥5,443,275,372.92 at the end of the previous year[10]. - The total liabilities increased to CNY 2,815,657,035.61 from CNY 2,732,960,522.70, representing a growth of approximately 3.0%[40]. - The total owner's equity rose to CNY 2,782,452,933.96 from CNY 2,710,314,850.22, indicating an increase of about 2.7%[43]. - The company's cash and cash equivalents increased to CNY 710,407,177.76 from CNY 684,346,623.61, reflecting a growth of approximately 3.4%[44]. - Total liabilities were reported at $2.73 billion, with current liabilities at $1.61 billion and non-current liabilities at $1.13 billion, reflecting a balanced liability structure[84]. - Total equity was reported at $2,410,517,531.36, with retained earnings of $447,445,773.88[91]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 25,752, indicating a stable shareholder base[14]. - The top ten shareholders held a combined 55.01% of the company's shares, with the largest shareholder owning 21.55%[14]. Operational Metrics - The weighted average return on equity was 2.18%, up from 1.71% in the same period last year, indicating improved profitability[10]. - Total operating costs decreased to ¥747,357,191.53 from ¥766,027,715.39, marking a reduction of about 2.2%[54]. - Research and development expenses rose to ¥22,398,036.17 from ¥18,945,458.98, which is an increase of approximately 18.9%[54]. - The company experienced a decrease in asset impairment losses from ¥11,219,810.17 to ¥6,552,555.46, a reduction of about 41.8%[54]. Changes in Financial Standards - The company adopted new financial instrument standards, adjusting "available-for-sale financial assets" of $18.65 million to "other equity instruments," with no impact on prior year financial metrics[81]. - The company did not provide retrospective adjustments for prior comparative data under the new financial instrument and leasing standards[92].

证券代码：002332 股票简称：仙琚制药 公告编号：2019-021 浙江仙琚制药股份有限公司 关于举办投资者接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司（以下简称"公司"）于2019年4月25日发布了《2018 年年度报告》，为便于广大投资者深入全面地了解公司情况，公司将举办投资者接 待日活动，现将有关事项公告如下： 一、活动时间 2019年4月30日（星期二）下午2:00-4:00。 二、活动地点 浙江省仙居县福应街道现代工业集聚区丰溪西路15号，公司会议室。 三、预约方式 参与投资者请于2019年4月28-29日（上午8:30-11:00，下午14:00-16:00）与公 司董事会秘书办公室联系，提前预约登记，并同时提供问题提纲，以便接待登记和 安排。 联系人：陈伟萍、沈旭红 电话：0576-87731138，传真：0576-87731138。 四、公司参与人员 董事长兼总经理张宇松先生、财务总监王瑶华女士、董事会秘书张王伟先生（如 有特殊情况，参与人员会有调整）。 五、注意事项 1、来访个人投资者请携带个 ...

Financial Performance - Operating revenue for the reporting period reached CNY 891,329,243.77, a year-on-year increase of 24.69%[8] - Net profit attributable to shareholders increased by 47.83% to CNY 88,364,696.46 for the reporting period[8] - Basic earnings per share rose by 42.86% to CNY 0.10[8] - The net profit attributable to shareholders for the year-to-date period was CNY 211,667,094.16, reflecting a 50.18% increase[8] - The net profit attributable to shareholders for 2018 is expected to increase by 30.00% to 60.00%, ranging from 26,861.91 to 33,060.82 million CNY[20] Assets and Liabilities - Total assets increased by 9.20% to CNY 5,606,778,444.21 compared to the end of the previous year[8] - Accounts receivable increased by 48.68%, up by 29,809.31 million CNY, mainly due to sales revenue growth and seasonal impacts in the industry[16] - Deferred income increased by 182.68%, up by 8,381.4 million CNY, mainly due to receiving policy relocation compensation[16] - Other receivables increased by 48.53%, up by 1,110.95 million CNY, mainly due to an increase in other temporary payments[16] Cash Flow and Expenses - Net cash flow from operating activities surged by 284.81% to CNY 151,213,433.16[8] - Cash paid to employees increased by 30.08%, up by 8,935.27 million CNY, due to higher salary expenses[17] - Cash paid for taxes increased by 40.7%, up by 7,747.55 million CNY, due to higher tax payments during the period[17] - Cash paid for fixed assets increased by 111.57%, up by 11,881.51 million CNY, primarily due to increased investments in fixed assets[17] Shareholder Information - The company reported a total of 29,339 common shareholders at the end of the reporting period[12] - The largest shareholder, Xianju County State-owned Assets Investment Group, holds 21.55% of the shares[12] - The company did not engage in any repurchase transactions during the reporting period[13] Research and Development - R&D expenses increased by 77.41%, up by 3,635.24 million CNY, attributed to higher R&D spending during the period[17] Commitments and Compliance - The company has no overdue commitments or non-operating fund occupation by controlling shareholders during the reporting period[19]

Financial Performance - The company's operating revenue for the first half of 2018 was ¥1,758,815,023.25, representing a 38.06% increase compared to ¥1,273,925,983.54 in the same period last year[19]. - The net profit attributable to shareholders of the listed company reached ¥123,302,397.70, a 51.91% increase from ¥81,168,064.69 in the previous year[19]. - The net cash flow from operating activities was ¥86,666,970.86, up 40.33% from ¥61,760,290.57 in the same period last year[19]. - Basic earnings per share increased to ¥0.13, reflecting a 44.44% rise from ¥0.09 in the previous year[19]. - Total assets at the end of the reporting period were ¥5,508,734,310.09, a 7.29% increase from ¥5,134,599,095.24 at the end of the previous year[19]. - The net assets attributable to shareholders of the listed company were ¥2,421,211,200.17, up 2.89% from ¥2,353,267,776.36 at the end of the previous year[19]. - The company reported a net profit excluding non-recurring gains and losses of ¥115,656,689.67, which is a 46.92% increase from ¥78,721,005.04 in the same period last year[19]. - The total profit reached CNY 179.25 million, reflecting a growth of 74.79% compared to the previous year[28]. - The company achieved operating revenue of CNY 1,758.82 million, a year-on-year increase of 38.06%[37]. Revenue and Sales - Revenue from the pharmaceutical sector amounted to ¥1,754,108,206.67, accounting for 99.73% of total revenue, with a year-on-year growth of 38.32%[48]. - Sales in the domestic market were ¥1,243,657,919.86, which is 70.71% of total revenue, showing a 14.30% increase compared to the previous year[48]. - International sales surged to ¥515,157,103.39, making up 29.29% of total revenue, with a remarkable year-on-year growth of 177.12%[48]. - Sales revenue from the respiratory formulation products surged by 174% to CNY 73 million[38]. Expenses and Costs - The company reported a total operating cost of CNY 1,592,911,238.22, which is a 36.0% increase from CNY 1,170,015,632.43 in the previous year[160]. - Financial expenses increased significantly to CNY 46,900,016.55, up from CNY 20,865,918.37, reflecting a rise of 124.5%[160]. - The company's gross profit margin improved, with operating costs rising by 28.50% to CNY 746.59 million[46]. Research and Development - The company has a strong R&D capability, collaborating with institutions like the Shanghai Institute of Materia Medica to enhance product quality and stability[34]. - Research and development expenses increased by 92.10% to CNY 47.32 million, indicating a strong focus on innovation[46]. - The company completed a Phase I clinical trial for a new drug, Omegastone Sodium, and is progressing to Phase IIa trials[39]. Investments and Subsidiaries - The company established a wholly-owned subsidiary in Hong Kong for pharmaceutical trading, with a registered capital of HKD 1 million[42]. - The subsidiary Taizhou Xianju Pharmaceutical Co., Ltd. achieved a revenue of RMB 65,086.36 million, a year-on-year increase of 55.11%[77]. - Newchem Co., Ltd., a wholly-owned subsidiary, reported revenue of RMB 28,437.52 million, contributing positively to the company's performance[78]. Cash Flow and Financing - The company reported a net increase in cash and cash equivalents of ¥82,964,756.06, a decrease of 79.65% due to increased debt repayment[47]. - The total cash flow from financing activities was negative at -¥10,523,058.12, a decline of 103.06% attributed to increased cash outflow for debt repayment[47]. - Cash inflow from borrowing was CNY 730,367,381.28, up from CNY 580,777,319.74, indicating an increase of about 25.8%[169]. Environmental Compliance - The company has established wastewater treatment facilities with a total capacity of 4,650 tons per day, ensuring stable operation with an efficiency rate exceeding 99%[115]. - The company complies with the "Comprehensive Discharge Standard for Wastewater" GB8978-1996, with COD emissions from the main plant limited to ≤480 mg/L and from other units to ≤500 mg/L[115]. - The company has a total of 60,000 cubic meters per hour of air pollution control facilities, ensuring compliance with the "Comprehensive Discharge Standard for Air Pollutants" GB16297-1996[116]. Shareholder Information - The total number of shares remained unchanged at 916,212,166, with unlimited sale shares increasing from 720,691,871 (78.66%) to 758,955,119 (82.84%) after the issuance of new shares[128]. - The largest shareholder, Xianju County State-owned Assets Investment Group Co., Ltd., holds 21.55% of shares, totaling 197,488,304 shares[135]. - The company’s major shareholders include state-owned entities and investment funds, with significant holdings such as 31,914,629 shares held by the State-owned Assets Supervision and Administration Commission[131]. Risks and Challenges - The company faces significant risks from industry policy changes, including "supply-side structural reform" and "capacity reduction," which could impact the pharmaceutical sector[81]. - Fluctuations in raw material prices may affect product costs, prompting the company to enhance domestic formulation sales and pursue high-end international registrations for raw materials[82]. - Rising comprehensive management costs, including depreciation, financial costs, and labor expenses, may impact profitability, leading the company to strengthen cost control measures[84]. Corporate Governance - The financial report for the first half of 2018 was not audited[148]. - The company has not initiated any non-raised fund investment projects during the reporting period[74]. - The company has included 19 subsidiaries in the consolidated financial statements, including Zhejiang Xianju Pharmaceutical Sales Co., Ltd. and others[189].

Financial Performance - The company's operating revenue for 2017 was ¥2,852,555,262.74, representing a 13.93% increase compared to ¥2,503,730,345.15 in 2016[19] - The net profit attributable to shareholders for 2017 was ¥206,630,126.59, a 41.35% increase from ¥146,186,888.11 in 2016[19] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥187,005,646.48, up 43.08% from ¥130,700,572.17 in 2016[19] - The basic earnings per share for 2017 was ¥0.23, an increase of 43.75% compared to ¥0.16 in 2016[19] - The net cash flow from operating activities was ¥167,466,085.22, a 7.42% increase from ¥155,905,554.91 in 2016[19] - The company achieved a revenue of 2.85 billion CNY in 2017, representing a year-on-year growth of 13.93%[48] - The net profit attributable to shareholders was 206.63 million CNY, an increase of 41.35% compared to the previous year[48] - The sales revenue from formulations reached 1.78 billion CNY, with self-operated and agency sales contributing 1.627 billion CNY, a growth of 21.1%[49] Assets and Liabilities - As of the end of 2017, total assets amounted to CNY 5,134.60 million, reflecting a growth of 41.81% from the end of 2016[20] - Cash and cash equivalents increased by 423.2 million CNY, a growth of 86.7%, primarily due to increased loan guarantees from Industrial and Commercial Bank of China and China Construction Bank[37] - Accounts receivable increased by 207.79 million CNY, a growth of 51.36%, attributed to sales growth and the merger with non-controlling enterprises[37] - The total restricted assets at the end of the reporting period amounted to CNY 445,438,552.59, primarily due to collateral for debts[86] Research and Development - The company continues to focus on research and development to enhance its product offerings and market position[6] - The company initiated 21 innovation projects in 2017, achieving breakthroughs in 16 of them, indicating a strong focus on R&D[54] - Research and development investment amounted to CNY 88,145,108.47, representing 3.09% of total revenue, a decrease of 0.39% from the previous year[79] - The number of R&D personnel increased by 24.29% to 261, accounting for 6.71% of the total workforce[79] Acquisitions and Investments - The company completed the acquisition of NewChem and EffeChem for €11 million, enhancing its steroid drug industry chain and competitive edge in high-end markets[56] - The company acquired 100% equity of NewChem and EffeChem in Italy, resulting in a goodwill increase of 602.57 million CNY, a growth of 100%[37] - The company invested $12 million in Occulo Holdings, LLC, acquiring a 36.5854% stake to expand its overseas R&D collaboration in the biopharmaceutical sector[56] Market Strategy - The company’s sales strategy focuses on enhancing market coverage and product recognition, particularly in the OTC and clinical lines[32] - The company aims to leverage its integrated advantages in raw materials and formulations to reduce overall costs and improve product gross margins[37] - The company is positioned as a key manufacturer of contraceptive drugs and a high-tech enterprise in the steroid drug sector, maintaining a leading market share[36] Risk Management - The company has identified several risks including industry policy risks and raw material price fluctuations, which are detailed in the management discussion section[6] - The company recognizes risks from industry policy changes, raw material price fluctuations, and bidding price reductions, and is prepared to adapt its strategies accordingly[123][124][125] - The company has identified risks associated with high investment and long cycles in new drug development, which may affect revenue expectations post-launch[127] Corporate Governance - The company is committed to maintaining transparency and accuracy in its financial reporting, as stated by its management[5] - The financial control system has matured, with comprehensive budget management effectively enhancing financial oversight and profitability[55] - The company has established a comprehensive internal control system and governance structure to protect the rights of shareholders and creditors[173] Shareholder Information - The company plans to distribute a cash dividend of ¥0.60 per 10 shares to all shareholders, based on a total of 916,212,166 shares[6] - The cash dividend distribution policy has been consistent, with no stock dividends or capital reserve transfers proposed for the past three years[134] - The company has committed to a minimum cash dividend ratio of 20% during significant capital expenditures, ensuring shareholder returns are prioritized[136] Environmental and Social Responsibility - The company has invested in environmental protection facilities, ensuring stable compliance with wastewater discharge standards, with a treatment capacity of 2,200 tons/day for its main facility[179] - The company actively participates in social responsibility initiatives, supporting local education, culture, and poverty alleviation efforts[176] - The company has established a strategic partnership with suppliers and customers, adhering to principles of openness, fairness, and justice in procurement processes[174]